These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

317 related articles for article (PubMed ID: 14740788)

  • 1. Oritavancin and tigecycline: investigational antimicrobials for multidrug-resistant bacteria.
    Guay DR
    Pharmacotherapy; 2004 Jan; 24(1):58-68. PubMed ID: 14740788
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tigecycline: an investigational glycylcycline antimicrobial with activity against resistant gram-positive organisms.
    Garrison MW; Neumiller JJ; Setter SM
    Clin Ther; 2005 Jan; 27(1):12-22. PubMed ID: 15763603
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A comparative review of the lipoglycopeptides: oritavancin, dalbavancin, and telavancin.
    Guskey MT; Tsuji BT
    Pharmacotherapy; 2010 Jan; 30(1):80-94. PubMed ID: 20030476
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tigecycline: a glycylcycline antimicrobial agent.
    Doan TL; Fung HB; Mehta D; Riska PF
    Clin Ther; 2006 Aug; 28(8):1079-1106. PubMed ID: 16982286
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment options for vancomycin-resistant enterococcal infections.
    Linden PK
    Drugs; 2002; 62(3):425-41. PubMed ID: 11827558
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oritavancin: an investigational lipoglycopeptide antibiotic.
    Karaoui LR; El-Lababidi R; Chahine EB
    Am J Health Syst Pharm; 2013 Jan; 70(1):23-33. PubMed ID: 23261897
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New lipoglycopeptides: a comparative review of dalbavancin, oritavancin and telavancin.
    Zhanel GG; Calic D; Schweizer F; Zelenitsky S; Adam H; Lagacé-Wiens PR; Rubinstein E; Gin AS; Hoban DJ; Karlowsky JA
    Drugs; 2010 May; 70(7):859-86. PubMed ID: 20426497
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recent advances in the treatment of infections due to resistant Staphylococcus aureus.
    Anstead GM; Owens AD
    Curr Opin Infect Dis; 2004 Dec; 17(6):549-55. PubMed ID: 15640709
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Newer treatment options for skin and soft tissue infections.
    Raghavan M; Linden PK
    Drugs; 2004; 64(15):1621-42. PubMed ID: 15257625
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tigecycline for the treatment of infections due to resistant Gram-positive organisms.
    Squires RA; Postier RG
    Expert Opin Investig Drugs; 2006 Feb; 15(2):155-62. PubMed ID: 16433594
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tedizolid: a novel oxazolidinone with potent activity against multidrug-resistant gram-positive pathogens.
    Zhanel GG; Love R; Adam H; Golden A; Zelenitsky S; Schweizer F; Gorityala B; Lagacé-Wiens PR; Rubinstein E; Walkty A; Gin AS; Gilmour M; Hoban DJ; Lynch JP; Karlowsky JA
    Drugs; 2015 Feb; 75(3):253-70. PubMed ID: 25673021
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Therapeutic perspectives of linezolid in the management of infections due to multiresistant Gram-positive pathogens].
    Manfredi R
    Recenti Prog Med; 2007 Mar; 98(3):143-54. PubMed ID: 17484159
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tigecycline.
    Pankey GA
    J Antimicrob Chemother; 2005 Sep; 56(3):470-80. PubMed ID: 16040625
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tigecycline: first of a new class of antimicrobial agents.
    Rose WE; Rybak MJ
    Pharmacotherapy; 2006 Aug; 26(8):1099-110. PubMed ID: 16863487
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Tigecycline: a new antibiotic in ongoing clinical development].
    Stahl JP
    Med Mal Infect; 2005 Feb; 35(2):62-7. PubMed ID: 15780894
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [New antimicrobials against Gram-positive organisms].
    Montejo M
    Nefrologia; 2008; 28 Suppl 6():119-24. PubMed ID: 18957022
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New antibiotic agents: problems and prospects.
    Weber DJ; Rutala WA
    Surg Infect (Larchmt); 2005; 6 Suppl 2():S-97-107. PubMed ID: 23577500
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A comparison of available and investigational antibiotics for complicated skin infections and treatment-resistant Staphylococcus aureus and enterococcus.
    Scheinfeld N
    J Drugs Dermatol; 2007 Jan; 6(1):97-103. PubMed ID: 17373167
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Unmet needs and prospects for oritavancin in the management of vancomycin-resistant enterococcal infections.
    Arias CA; Mendes RE; Stilwell MG; Jones RN; Murray BE
    Clin Infect Dis; 2012 Apr; 54 Suppl 3(Suppl 3):S233-8. PubMed ID: 22431854
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetic/pharmacodynamic profile for tigecycline-a new glycylcycline antimicrobial agent.
    Meagher AK; Ambrose PG; Grasela TH; Ellis-Grosse EJ
    Diagn Microbiol Infect Dis; 2005 Jul; 52(3):165-71. PubMed ID: 16105560
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.